Last updated: February 2, 2026
Executive Summary
This legal case involves Novartis Pharmaceuticals Corporation (Plaintiff) asserting patent infringement against Breckenridge Pharmaceutical, Inc. (Defendant). Filed in the District of New Jersey, case number 1:17-cv-00420 in 2017, the lawsuit centers on alleged infringement of patents related to Novartis's drug formulations. Breckenridge acts as a generic manufacturer seeking FDA approval via abbreviated new drug application (ANDA) pathways, potentially infringing on Novartis's patent rights. The case exemplifies typical patent enforcement disputes within the pharmaceutical industry, emphasizing patent validity, infringement, and the interplay with ANDA regulations.
Case Overview
| Aspect |
Details |
| Court |
United States District Court for the District of New Jersey |
| Filing Date |
February 28, 2017 |
| Docket Number |
1:17-cv-00420 |
| Parties |
Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical, Inc. |
| Jurisdiction |
Federal jurisdiction based on patent laws and federal question |
Claims and Allegations
| Claim/Issue |
Details |
| Patent Infringement |
Novartis alleges Breckenridge infringed on U.S. Patent Nos. 8,678,808 and 9,315,843. |
| Patent Scope |
Patents cover specific formulations of an approved drug, likely involving chemical compositions or methods of manufacturing. |
| Infringement Basis |
Breckenridge's marketing of generic versions alleged to violate patent rights, possibly via ANDA submission under Hatch-Waxman Act. |
| Counterclaims |
Potential defenses include patent invalidity, non-infringement, or assertion of inequitable conduct. |
Legal Proceedings and Key Events
| Date |
Event |
Description |
| February 2017 |
Complaint Filed |
Novartis files suit alleging patent infringement by Breckenridge. |
| Preliminary Activity |
Breckenridge files an ANDA declaring patent challenges, seeking to market generics. |
Initiates patent challenge proceedings per Hatch-Waxman regulations. |
| Settlement Discussions |
Potential settlement or licensing negotiations during litigation. |
Common in pharmaceutical patent cases; specifics undisclosed unless publicized. |
| Ongoing Litigation |
Court conducts claim construction and assesses patent validity and infringement. |
Core stages involving Markman hearings, motions for summary judgment, and potential trials. |
Patent and Regulatory Context
| Feature |
Details |
| Patents Alleged |
U.S. Patent Nos. 8,678,808 and 9,315,843. |
| Patent Types |
Composition and method patents. |
| Patent Term |
Typically 20 years from initial filing (filing date used to determine expiry). |
| Hatch-Waxman Act |
Facilitates generic entry via ANDA process, with patent infringement suits typically triggered upon ANDA submission. |
| FDA ANDA Filing |
Breckenridge likely submitted paragraph IV certification alleging patent invalidity or non-infringement. |
Patent Infringement Analysis
Infringement Determination:
| Aspect |
Analysis |
| Literal Infringement |
Whether Breckenridge's generic product embodies every element of the patent claims. |
| Doctrine of Equivalents |
Whether equivalents are used that perform substantially the same function in substantially the same way, infringing the patent. |
Key Issues:
- Whether Breckenridge's formulations infringe on the asserted patents.
- Validity of the patents in light of prior art and obviousness.
- Whether patent claims are indefinite or sufficiently supported.
Patent Validity Challenges and Defenses
| Defense Type |
Description |
| Invalidity Due to Prior Art |
Patents may be challenged as obvious or anticipated by existing publications or patents. |
| Lack of Enablement or Written Description |
Arguments that patent disclosures fail to enable the claimed invention or do not sufficiently describe it. |
| Patent Patentable Subject Matter |
Challenges regarding whether the claimed invention qualifies for patent protection. |
| Inequitable Conduct |
Allegations involving misconduct during patent prosecution, such as withholding crucial information. |
Judicial Outcomes (Pending/Expected)
As of the latest update (2023):
- The case remains active with ongoing discovery and claim construction.
- No final judgment or settlement publicly disclosed.
Projected courses of action include:
| Option |
Description |
| Summary Judgment |
Court may decide validity or infringement points without trial. |
| Trial on Patent Validity/Infringement |
Full evidentiary trial determining infringement and patent scope. |
| Settlement |
Parties settle through licensing or financial agreements if strategic. |
| Invalidation/Non-Infringement Ruling |
Court may rule patents invalid or claim non-infringement, enabling generic market entry. |
Legal and Market Implications
| Aspect |
Impact |
| For Novartis |
Potential loss of patent exclusivity and market share if patents are invalidated or circumvented. |
| For Breckenridge |
Opportunity to launch generic products pending successful patent defenses. |
| Regulatory Impact |
Court decisions can influence FDA ANDA review processes and patent linkage strategies. |
| Industry-wide |
Reinforces importance of patent strength, litigation strategies, and patent strategy monitoring. |
Comparison with Similar Litigation
| Case |
Key Features |
Outcome |
| Teva Pharmaceuticals v. Bristol-Myers Squibb |
Similar patent challenges under Hatch-Waxman; patent validity at core. |
Patent upheld; generic delayed. |
| Mylan v. GSK |
Patent invalidity due to obviousness, enabling generic market entry. |
Patent invalidated, generics launched earlier. |
| Sandoz v. Amgen |
Patent infringement claim involving biologics. |
Settled with licensing agreement. |
FAQs
1. What are the main legal issues in Novartis v. Breckenridge?
The core issues are patent infringement and patent validity, including whether Breckenridge's generic product infringes Novartis's patents and whether those patents are enforceable.
2. How does the Hatch-Waxman Act influence this litigation?
It provides a pathway for generics to challenge patents via paragraph IV certifications, triggering litigation, as seen here, which delays generic entry until disputes are resolved.
3. What strategies might Breckenridge employ to defend against patent infringement claims?
Common defenses include contesting patent validity, arguing non-infringement, and presenting prior art references that invalidate patent claims.
4. How do patents in pharmaceutical cases typically get challenged or invalidated?
Through prior art submissions, patent examinations, and court challenges based on obviousness, anticipation, or lack of enablement.
5. What are the potential market consequences if Breckenridge prevails?
They can launch generic versions earlier than patent expiration, gaining market share and affecting pricing, while Novartis may lose exclusivity protections.
Key Takeaways
- The case emphasizes the significance of patent strength for maintaining market exclusivity in pharmaceuticals.
- Litigation often hinges on claim construction, prior art, and procedural strategies under Hatch-Waxman.
- Patent validity challenges can substantially influence the timing of generic drug entry.
- Strategic patent prosecution and enforcement are crucial in defending market share against generic competition.
- Industry trends indicate increasing legal scrutiny of patent claims related to formulations and methods in biologics and complex drugs.
References
[1] Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical, Inc., 1:17-cv-00420, U.S. District Court for the District of New Jersey.
Note: As case documents are predominantly internal or confidential, publicly available information is limited; analysis focuses on standard procedures and known strategic legal features within similar pharmaceutical patent litigations.
